Rapport Therapeutics, Inc. RAPP Ratios & Valuation
| FY'25 | FY'24 | ||
|---|---|---|---|
| Returns | |||
| Return on equity | -28.2%— | —— | |
| Return on assets | -26.9%+6.3pp | -33.3%— | |
| Return on invested capital | -36.1%— | —— | |
| Liquidity | |||
| Current ratio | 26.2×-9.2× | 35.3×+18.2× | |
| Quick ratio | 26.2×-9.2× | 35.3×+18.2× | |
| Cash ratio | 2.8×-3.7× | 6.5×-1.5× | |
| Leverage | |||
| Debt-to-equity | 0×0.0× | 0×— | |
| Debt-to-assets | 0×0.0× | 0×0.0× | |
| Per Share | |||
| Book value per share | $12.45-15.5% | $14.73+187% | |
| Valuation | |||
| Market capitalization | $1.45B+123% | $648.87M— | |
| Enterprise value | $1.4B+137% | $593.54M— | |
| Price / book | 3×+0.9× | 2.1×— | |
| Free cash flow yield | -6.1%+4.3pp | -10.4%— | |
| Earnings yield | -7.7%+4.4pp | -12.1%— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Rapport Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Rapport Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.